Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant anlotinib plus PD-1 inhibitor after surgery for locally advanced oral squamous cell carcinoma
ChiCTR2400093383Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib, pembrolizumab and penpulimab in Oral Mucosal Carcinoma, sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: 1-year recurrence-free survival rate. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2400093383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093383.